Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Direct
36 Pages - GMD18630
$3,500.00

Summary

According to the recently published report 'Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022'; Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Metabotropic glutamate receptor 7 is a protein encoded by the GRM7 gene. G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase.

The report 'Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022' outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Undisclosed and Women's Health which include indications Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Drug-Induced Dyskinesia, Infantile Spasm (West Syndrome), Lennox-Gastaut Syndrome, Opium (Opioid) Addiction, Parkinson's Disease, Post Partum Depression (Maternal Depression / Postnatal Depression), Rett Syndrome, Status Epilepticus, Unspecified and Visceral Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- The report reviews Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Overview
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bio-Pharm Solutions Co Ltd
Domain Therapeutics SA
Nobias Therapeutics Inc
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Drug Profiles
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-095435 - Drug Profile
Product Description
Mechanism Of Action
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LSP-29166 - Drug Profile
Product Description
Mechanism Of Action
NB-001 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize mGlu7 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Dormant Products
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Discontinued Products
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) - Product Development Milestones
Featured News & Press Releases
Jul 09, 2019: Addex to lead mGlu7 NAM-focused PTSD consortium
Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Bio-Pharm Solutions Co Ltd, 2022
Pipeline by Domain Therapeutics SA, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

$3,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838